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This workbook is part of a series in-
tended to educate programme plan-
ners, managers, staff and other deci-
sion-makers about the evaluation of
services and systems for the treatment
of psychoactive substance use disor-
ders. The objective of this series is to
enhance their capacity for carrying out
evaluation activities. The broader goal
of the workbooks is to enhance treat-
ment efficiency and cost-effectiveness
using the information that comes from
these evaluation activities.
This workbook is about process
evaluation. Process evaluation in-
volves assessing the extent to which
your treatment service or system is
serving the people for whom it was
intended, as well as the processes
involved in programme operation
and delivery. The workbook focuses
on evaluations that assess:
• who does or doesn’t use your
treatment service or system
• the way people become involved
and enter treatment
• the intensity, quality and sequenc-
ing of treatment activities
Overview of
workbook series
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Process evaluations are at aimed at enhanc-
ing your current programme by understand-
ing it more fully. Process evaluations mea-
sure what is done by the programme, and
for whom these services are provided. Ide-
ally, process evaluations assist in the identifi-
cation of “active ingredients” of treatment,
and assess whether a programme is meeting
accepted standards of care.
In general, process evaluations pose ques-
tions in two areas: coverage and process.
Coverage
• What proportion of those who might need
the service(s) actually used it/them?
• Has the service, or network of services
served the intended clients?
• What were the demographic and clinical
characteristics of clients?
• What proportion of clients completed
treatment and what were the characteris-
tics of those who dropped out?
What is a process
evaluation?
Process
• By what route have clients entered
treatment?
• How long was the waiting list and how
has it been managed?
• What actually happened to clients in treat-
ment and is this what was intended?
• Were treatment plans consistent with the
results of assessment?
• What was the average length of stay or
the average number of appointments kept?
• How were discharge plans developed?
• Were services within the community treat-
ment network well-co-ordinated?
Coverage and process questions can be
asked at different levels of treatment (see
Framework workbook): activity, service,
agency, or system levels. Procedures for dif-
ferent levels will be discussed in detail.
Test your knowledge. Write down whether
each of the following questions is a cover-
age question or a process question:
a) Is the programme serving clients it was
intended to serve?
b) How many direct contact hours does each
client receive?
c) What is the average age of programme
participants from each referral source?
d) What percent of clients complete the
programme?
(Answers: coverage, process, coverage, process)
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Process evaluations are undertaken for a
variety of reasons. They are most useful when
clear objectives have been developed for the
Accountability
evaluation and the intended users are involved
at the planning stage. The main reasons for
conducting process evaluations are:
Programme development
and improvement
Why do a process
evaluation?
dence that the funds are being used as ex-
pected. Clients, their families, referral agents
and the public at large expect managers of
treatment services and systems to be ac-
countable for their use of resources and level
of service provision.
How can the programme be improved?
Process evaluations can provide in-depth
information about the functioning of treat-
ment services and systems, and pin-point
areas where improvements might be made.
For example, a process study might show
duplication in the assessment process.
To help others set up similar
services or networks
How can the programme be expanded to
other areas? If a service or treatment system
achieves high rates of success with people
with PSU disorders, it will be desirable to
replicate this service or system in other
places. Information therefore will be needed
about clients, staffing, and the inter-relation-
ship of clinical activities.
Is the programme accomplishing what it is
expected to accomplish? Many groups want
to know the answers to this question. Gov-
ernments and social agencies that sponsor
treatment for PSU disorders sometimes re-
quire recipients of funding to provide evi-
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When doing a process evaluation, it is im-
portant that you follow the general steps
of evaluation planning and implementation
as outlined in Workbooks 1 and 2. In ad-
dition, it is important to read through the
1. Questions about coverage at the
activity, service, or agency level
sess for purposes of monitoring programme
coverage. The range of information that you
collect will depend somewhat on your level
of resources (Step 2 of evaluation planning -
Workbook 1). Regardless, it is important that
you gather enough information to compare
the characteristics of your clients to the type
of client reflected in your programme objec-
tives.
Specific instruments and items that can be
used to measure variables related to
programme coverage are identified in Table
1. Many of these instruments are in the
public domain and are included in a Di-
rectory of Outcome Measures published
by the Addiction Research Foundation
(ARF) of Ontario, Canada. The address
for the ARF and those measures considered
most relevant for this workbook are included
in Workbook 1, Appendix 2. The measures
can be used to describe clients at the time of
intake. Many can also be used at follow-up.
Because most of these questionnaires were
developed in Western countries, care should
be taken to ensure that the questions are
appropriate and understandable in your cul-
ture and setting.
Example questions:
• What proportion of those who might need
the activity, service, or agency actually
used it?
• Has the activity, service, or agency served
the intended clients?
• What were the demographic and clinical
characteristics of clients?
• What proportion of clients completed
treatment and what were the characteris-
tics of those who dropped out?
When evaluating programme coverage at the
activity, service, or agency level (see Frame-
work manual for definitions), you typically
include information on clients’ age, gender,
education and employment status, source of
referral, place of residence, current PSU and
related problems, participation in previous
treatment and stability in various life areas.
Information on these variables is required
both to plan treatment services and provide
accountability information.
There are no established guidelines for se-
lecting other characteristics of clients to as-
It is important
that you gather
enough
information to
compare the
characteristics
of your clients
to the type of
client reflected
in your
programme
objectives.
information here, to provide you with
specialised details about conducting differ-
ent kinds of process evaluations. Four cat-
egories of process evaluation questions are
presented below.
How to do a
process evaluation
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Table 1: Measures available for basic coverage variables
Variables
Age
Gender
Marital Status
Education
Employment and financial status
Source of referral
Type of residence
Involvement in health and justice system
Involvement of other treatment services
Treatment Unit Characteristics
Alcohol consumption
Other PSU
Adverse consequences of alcohol use
Adverse consequences of other PSU
PSU, harmful use and dependence
HIV-Risk behaviours
General mental health
Physical health
Motivation for treatment
Measures
Recorded in years
Male, female
Typical items can be found in resources such as the ARF Directory of
Outcome Measures (undated), the Resource Manual for the How Good is
Your Drug Abuse Treatment Programme (NIDA, 1993), the Alcoholism
Treatment Assessment Instruments (Lettieri et al., 1984), and the Drug
Abuse Instrument Handbook (Nehemkis et al., 1976)
Use of health and correctional services are captured by a Health and Corrections
Utilisation Form appropriate for process evaluation and telephone follow-
up (Workbook 1, Appendix 2). The Addiction Severity Index (ASI) has
Legal and Employment Subscales (McLellan et al., 1988)
Treatment Unit Form (available from EMCDDA)
Examples of quantity/frequency measures are included in the ARF Directory
of Outcome measures (undated)
Lifetime Drinking History (Skinner, 1979)
Timeline Followback Method (Sobell and Sobell, 1988)
Alcohol subscale of the ASI (McLellan at al., 1988)
(see Workbook1, Appendix 2 for a brief format (DHQ) that is useful for both
process evaluation and telephone follow-up)
Examples are included in the ARF Directory of Outcome Measures (undated)
Drug subscale of the ASI (McLellan et al., 1988)
(see Workbook 1, Appendix 2 for a brief format (DHQ) that is useful for
both process evaluation and telephone follow-up)
Examples of some approaches to measuring consequences other than
dependence are included in the ARF Directory of Outcome Measures
Short Alcohol Dependence Data (Raistrick et al., 1983)
Alcohol Dependence Scale (Horn et al., 1984)
Adverse Consequences of Alcohol Scale (Miller et al., in press)
Drug Abuse Screening Test (Skinner, 1982)
The AUDIT (WHO, 1992)
The Composite International Diagnostic Interview (Robins et al., 1989)
WHO-CIDI, M -CIDI (Witchen, 1994)
Alcohol Dependence Scale (Horn et al., 1984)
(see Workbook 1, Appendix 2 for a brief (DHQ) format that is useful for
both process evaluation and telephone follow-up)
Symptom Checklist 90 (Derogatis, 1977)
Profile of Mood States (McNair et al., 1971)
Psychiatric Status subscale of the ASI (McLellan et al., 1988)
Health Questionnaire (Brodman et al., 1949)
Medical problems subscale of the ASI (McLellan et al., 1988)
McArthur Scale (Gardner et al., 1993)
Treatment Entry Questionnaire (Wild, 1996)
(see Workbook 1, Appendix 2 for a brief questionnaire)
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Other client variables relevant to the evalu-
ation of programme coverage are: situa-
tions associated with PSU, self-efficacy
and coping skills, depression and other
aspects of psychological well-being and
social/marital relationships. Many of these
variables have been shown to influence
treatment compliance and outcomes, and
an assessment of these variables is recom-
mended if resources permit. Instruments
that measure these factors are noted in
Table 2.
Example case: research
about coverage at the
activity, service, or agency
level
This example programme is the prevention
component of a youth PSU services agency.
Clients range in age from 16 to 24, and are
referred to the programme by a variety of
sources. The four session prevention
programme is designed for youth with a low
level of PSU and PSU-related problems.
Research questions:
1) Has the number of referrals from schools
and probation services increased from the
previous year?
2) What percent of clients are ages 16-19?
Table 2: Measures available for other client characteristics
Variables Measures
PSU situations Inventory of Drinking Situations (Annis et al., 1987)
Inventory of Drug Use Situations (Annis and Graham, 1991)
Self-efficacy and coping skills Drug Taking Confidence Questionnaire (Annis and Martin, 1985)
Situational Confidence Questionnaire (Annis and Graham, 1988)
Coping Behaviours Inventory (Litman et al., 1983)
Depression Beck Depression Inventory (Beck at al., 1961)
CES-D (Radloff, 1977)
Anxiety State-Trait Anxiety Inventory (Spielberger et al., 1970)
Self-esteem/confidence Rosenberg Self-esteem Scale (Rosenberg, 1965)
Family relationships/ functioning Family Assessment Measure (Skinner et al., 1983)
Family Environment Scale (Moos and Moss, 1986)
Family/Social Subscale of the ASI (McLellan et al., 1988)
Marital relationships/ functioning Dyadic Adjustment Scale (Sapinier, 1976)
Perceived support from friend and family Perceived Social Support - Family and Friends
(Procidano and Heller, 1983)
3) What is the average age of programme
participants from each referral source?
What resources were needed to gather
this information?
Information is collected on an ongoing basis.
The programme secretary spent about three
hours entering information on 200 clients into
the central database.
How were the data collected?
As each client is admitted to the prevention
programme, counsellors record his/her sex,
age, and referral source on a form. At the
end of the year, all forms are forwarded to
the secretary for tabulation.
How were the data analysed?
Number and percent of clients from each
referral source was calculated and compared
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to last year's figures. Average age overall was
calculated, as well as average age from each
referral source.
What did they find out?
The results indicated that the number of re-
ferrals from the legal system and from schools
has increased substantially from last year.
Eighty-seven percent of participants were in
the 16-19 age group. The average age, over-
all, was 17.8 years. Average age did not vary
greatly based on referral source.
What will they do with this information?
The programme staff expects continuing in-
creased number of referrals. As a result, they
plan to expand their programme in the com-
ing year.
2. Questions about coverage at the
system level
Example questions:
• How many treatment programmes exist
in the region?
• How many clients are seen by each
programme in a year?
• Are there differences in the types of
clients seen at each programme?
Many variables of interest in coverage stud-
ies that involve networks of services are the
same as those for studies of individual activi-
ties, services, or agencies. The analysis fo-
cuses on similarities and differences in client
profiles across agencies. The profile of all
clients served by the network is of consider-
able interest.
The scope of information collected to moni-
tor coverage across a network of services
will likely be smaller than that collected by
any one service. This is due largely to the
difficulty in achieving agreement among par-
ticipating programmes on how key client
characteristics should be measured. Practi-
cal issues of managing and analysing the in-
formation keep the data collection focused
on critical pieces of information required for
monitoring coverage of the overall treatment
system.
As with the selection of variables within indi-
vidual services, your selection at the system-
level should be guided by objectives and in-
ter-agency agreements. For example, your
treatment network may determine that cli-
ents with significant PSU and psychiatric co-
morbidity should be fully assessed and treated
in particular facilities with adequately trained
staff. Your system evaluation plan should then
include routine monitoring of the flow of ap-
propriate clients to these designated facili-
ties. Similarly, a system with agreed upon ad-
mission and discharge criteria based on
problem severity would routinely monitor the
severity of clients'problems across all
programmes in order to ensure that the ap-
propriate match to treatment is being made
and that the admission criteria are being fol-
lowed system-wide.
Example case: research
about coverage at the
system level
A new detoxification programme was devel-
oped. The programme has 16 beds, and is
allotted to clients from the outlying region.
There are several other detoxification
programmes within the city boundaries.
Research questions:
1) What percent of clients in the new detoxi-
fication programme lives in the outlying area,
and what percent comes from within the city
boundaries?
2) Are the clients from the different detoxifi-
cation programmes different in terms of age,
sex, or PSU?
The analysis
focuses on
similarities and
differences in
client profiles
across
agencies.
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What resources were needed to answer
this question?
Managers from the different detoxification
centres collaborated to devise a one-page
data collection form. This form was copied
and distributed to clinicians for use with all
new clients.
How were the data collected?
Upon admission to each detoxification
programme, the admitting clinician com-
pletes a one page form, which includes the
client’s age, sex, address, and a series of
questions about current PSU: type(s) and
frequency. These forms are forwarded to
a central site, where they are recorded in
a log book and maintained by the
programme data manager.
How were the data analysed?
Clients’ data were divided according to dif-
ferent detoxification sites. Within the new
detoxification site, clients’ addresses were
coded for (1) living within the outlying area,
or (2) living within the city. The percentage
of clients from each geographic area was
calculated. Clients’ ages, sexes, and PSU
patterns were calculated across detoxifica-
tion centres.
What did they find out?
The majority of clients in the new detoxifi-
cation centre lived in the outlying area
(87%). Clients from different detoxifica-
tion sites differed according to age (23, 35,
and 19 years) and percent male (66%,
53%, and 78%), but not by PSU type or
frequency.
What did they do with this information?
Based on the results, administrators felt com-
fortable that they were serving the desired
population with the new detoxification cen-
tre. No changes were implemented.
3. Questions about treatment
process at the activity, service, or
agency levels
Example questions:
• By what route did clients enter treatment?
• What actually happened to clients in treat-
ment and is this what was intended?
• What was the average length of stay or
the average number of appointments kept?
Treatment processes in activity, service, or
agency level evaluations include those that
influence entry into treatment and the admin-
istrative and clinical activities to which cli-
ents are exposed while in treatment. Vari-
ables concerning treatment entry include the
extent to which potential clients and referral
agents are aware of the service in question
and factors that influence one's decision to
seek or recommend treatment. This includes
coercive factors in the justice system. Two
questionnaires that explore these issues from
the client's perspective are included in Table
1 (McArthur Scale (Gardner et al., 1993);
Treatment Entry Questionnaire (Wild,
1996)). Other, more qualitative, questions
for clients may be:
• How did you first hear about (name of
services)?
• Who first suggested that you come to
(name of service)?
• Why did you come to (name of service)
as opposed to somewhere else?
• Are you under any pressure to come to
(name of service) , for example, from
the courts, your employer, school or
family?
Treatment
processes in
activity, service,
or agency level
evaluations
include those
that influence
entry into
treatment and
the
administrative
and clinical
activities to
which clients
are exposed
while in
treatment.
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Qualitative questions for community pro-
fessionals about treatment referrals may
be:
• How did you first hear about (name of
service)?
• Are you aware of the services offered and
the intake process?
• Have you referred clients in the past/do
you intend to refer clients in the future?
• What types of clients do you refer/not refer
and why?
Treatment process evaluations serve two
important functions:
Active ingredients
Evaluations of treatment processes are
essential in order to identify the “active in-
gredients” of treatment. The clinical pro-
cesses in many treatment services may be
quite complex and encompass a variety of
distinctive components. Such components
may include, for example, intake, assessment,
group or individual treatment, discharge plan-
ning and follow-up.
Standards of care
Process evaluations also help to make judge-
ments about the quality of administrative and
clinical processes treatment services, against
local or more widely used standards about
what is expected in a “quality” treatment fa-
cility. Explicit standards for treatment services
for PSU disorders have been developed in
some regions. One set of standards has been
developed by the World Health Organiza-
tion (WHO, 1993). These standards are
listed below. Example items may not be ap-
plicable to your specific settings, but general
areas can be used as a guide for developing
your own standards.
Basic standards are essential for any treat-
ment organisation. Evaluation of adherence
to these standards is an important type of
process evaluation.
Basic standards
are essential for
any treatment
organization.
WHO standards of care in PSU treatment
a) Standards on access, availability, and
admission criteria
Examples:
• services are available irrespective of
age or gender of all potential patients
• services are easily accessible with re-
gard to location, travelling time, and
transportation
b) Standards on assessment
Examples:
• An initial assessment is made in order
to prioritise interventions in a co-
ordinated treatment plan
• Methods for determining quantities of
PS(s) ingested are available
c) Standards on treatment content, pro-
vision, and organisation
Examples:
• A record of patient management,
progress, and onward referral is kept
and updated regularly to ensure conti-
nuity of clinical care
• The range of relevant treatment op-
tions available is described to the pa-
tient
d) Standards on discharge, aftercare,
and referral
Examples:
• Discharge is based on determination
of patient recovery status
• Attention is paid to further treatment
and support which may be required
e) Standards on outreach and early in-
tervention
Examples:
• There is promotion in settings other than
health facilities (e.g., workplace, schools)
of early intervention
• Primary health care, other health care,
welfare staff, and police are trained dur-
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ing their education in the recognition,
basic management, and referral of in-
dividuals with drug-related disabilities
f) Standards on patients’ rights
Examples:
• Patients are fully informed of the na-
ture and content of the treatment as
well as the risks and benefits to be ex-
pected
•  Physical restraint is not used to detain
or restrain patients who are legally
competent to leave
g) Standards on physical aspects of
treatment settings
Examples:
• The physical environment is designed to
protect the well-being of patients
• Patients being treated on an inpatient/
residential basis have access to pri-
vacy and recreational facilities
h) Standards on Staffing
Examples:
• Appropriately trained staff are either
available on site in treatment
programmes, or are available on call
at all times when treatment is being
provided
• Staff have regular supervision by se-
nior staff, peer review, and case con-
ferences to maintain quality of service
delivery
Assessment of adherence to basic standards
are not the same as continuous quality im-
provement (Rush and Krywonis, 1996), in
which managers and staff seek to constantly
improve programme performance. Some dif-
ferences are listed on this page:
Continuous quality
improvement
• is driven primarily by the goals of high
customer satisfaction
• strives to raise the performance of ev-
eryone, not just the poor performers
• process empowers staff to become in-
volved and effect real change in their
work environment
• focuses on the whole organisation –
both within and across departments
• focuses on prevention but employs a
problem-solving approach using a wide
range of tools and analytic methods to
identify causes, understand processes,
measure and track
• focuses on the quality and inter-rela-
tionship of all services, products and
processes for clients and other custom-
ers (e.g., families, staff). Looks beyond
clinical staff to clients, their families,
community stakeholders and internal
staff. Everyone is a potential customer
performance and monitor the changes
to ensure gains are sustained
Assessment of
basic standards
• assesses current practice against pre-es-
tablished performance criteria or standards
• focuses on departments or individuals
whose performance deviates from ac-
cepted values or standards
• staff are not closely involved in setting the
performance standards or assessing their
achievement
• occurs within specific departments and as-
sesses the functioning of that department
• focuses on programme environment and
activities; tends not to address client out-
comes
• focuses on the quality of clinical care de-
livered by professionals and received by
clients
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If your organisation uses a continuous qual-
ity improvement (CQI) approach, it is im-
portant that you consider how the evaluation
relates to this broader process. CQI is not
sufficient, in isolation, to make judgements
about standards of care. Nonetheless, it is a
useful option to consider for some agencies.
Creating a CQI Programme
If you are interested in initiating a CQI
programme, a comprehensive approach is
required. This includes:
• conducting self-assessments to determine
organisational readiness to implement
CQI
• developing a supporting organisational
structure, culture and leadership
• understanding the programme’s main
functions, treatment processes and client;
• developing and training CQI teams and
facilitators
• planning a reward and recognition
programme
• designing and adapting CQI approaches
and materials to meet the needs of the
agency
• reviewing and/or designing information
systems necessary to support CQI ac-
tivities
• infusing a CQI philosophy that guides all
the organisations and staffs actions and
activities
It is important not to be discouraged with
the scope of the task. Agencies must deter-
mine the rate of CQI implementation that is
feasible within the context of available re-
sources and other internal and external pres-
sures. To be successful, implementation of a
CQI programme needs to become part of
ongoing strategic planning and management.
Example case: research
about treatment process at
the activity, agency, or
service level
This example programme is a PSU assess-
ment/referral service. The mandate of the
programme is to perform a comprehensive
assessment of every client and to refer cli-
ents to appropriate services within the agency
to begin within 2 months of the intake.
Research questions
1) What was the average number of days
between the intake and the first sched-
uled appointment?
2) What percent of clients did not show for
their first scheduled appointment?
What resources were needed to answer
this question?
In order to keep statistics on appointments
and attendance, the programme secretary
maintained the database on a weekly basis.
How were the data collected?
Attendance data were recorded on daily
appointment logs kept by the assessment
workers. The intake worker kept a record
of the initial intake and the date of the initially
scheduled assessment appointment. If a
change was made in the appointment, the
intake worker reported this to the secretary,
who updated this in the database.
How were the data analysed?
The information required for the evaluation
already existed in the database. The
programme secretary completed the follow-
ing descriptive statistics:
1) average number of days between intake
and first scheduled appointment
2) percent of referrals who attended at least
one orientation session
What did they find out?
There were 984 clients who scheduled at
least one assessment appointment during the
past year. The average length of time
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between the intake and first assessment
appointment was 67 days. Seventy-six
percent of patients had their first appointment
within 60 days of their intake. Thirty-nine
percent of clients were “no-shows” for their
assessment appointments.
What did they do with this information?
Based on the finding that 34 percent of pa-
tients were not meeting the mandated time
frame of 2 months between assessment and
first appointment, and that about 40 percent
were “no-shows” to their appointments, the
agency decided to reorganise so that first
appointments occurred on a specified day
of the week at a specific time. Several staff
members were on-call during that time frame
to see people as they appeared for their ap-
pointments. With this new system, more pa-
tients could be scheduled earlier, and the
inefficiency of staff waiting for “no-shows”
was greatly reduced.
4. Questions about treatment
process at the system level
Example questions:
• Are different treatment programmes aware
of one another?
• Do different treatment programmes refer
clients to one another?
• What is the relationship between general
medical services and specialised treat-
ment programmes?
The study of PSU treatment systems is a new
field of research and there is no agreement
concerning the types of variables that should
be considered in system-level process evalu-
ations. One of the first steps in system-level
evaluation is to define the boundaries of the
system itself. You may choose, for example,
to focus only on the specialised alcohol and
drug treatment agencies in a particular juris-
diction. Increasingly, however, system-level
planners and local providers are concerned
with co-ordination among specialised treat-
ment programmes and between these
programmes and other services that clients
may need (e.g. mental health services, em-
ployment services, services in the justice sys-
tem) (Institute of Medicine, 1990).
Co-ordination can be defined as the degree
to which agencies in a given network col-
laborate and exchange information and re-
sources (staff, funds, material etc.). Co-or-
dination is typically assessed using reports
and ratings from directors or managers of
agencies that are expected to work together
in service planning and delivery. The focus
of these reports and ratings has been on:
• mutual awareness - the extent to which
staff know about each other and their re-
spective programmes
• frequency of interaction - how often
key staff meet to discuss work-related
issues
• frequency of cross referrals - how often
or how many clients are referred to and
from different services in the network
• information exchange - the extent to
which services exchange information
• staff sharing or exchange - staff of dif-
ferent services are permanently or tem-
porarily shared or loaned
• other resource exchanges - the extent
to which services share funds, meeting
rooms, materials or other resources
... are
concerned with
co-ordination
among
specialised
treatment
programmes
and between
these
programmes
and other
services that
clients may
need.
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• consultations and case conferences -
exchanges that concern the treatment of
specific clients
• overlapping boards - the number of
members in common to community
boards of different services
• normalisation of agreements - the ex-
tent to which services have developed
formal agreements to co-ordinate their
activities
Example case: research
about treatment process at
the system level
This example is a network of PSU treatment
centres that are interested in knowing more
about assignment to treatment for clients who
have PSU problems. The network has cen-
tres in the city centre and in outlying areas.
Research questions:
1) For each centre, from where do referrals
originate?
2) What is the waiting time for services within
each centre?
What resources were needed to answer
this question?
Case workers recorded referral information
as part of their intake interviews. Consolida-
tion of these data and tabulation of results
were completed by one of the programme's
secretaries on a monthly basis, taking about
one hour per month. Each programme man-
ager completed an interview and question-
naire that assessed current treatment ser-
vices.
How were the data collected?
The data collection occurred in two parts.
For the first part, assessing the referral source,
case workers recorded this information as
part of their intake interviews. Consolidation
of these data and tabulation of results were
completed by a programme secretary on a
monthly basis. For the second part, assess-
ing treatment services, two interviewers were
dispatched to each programme to collect data
on waiting times for current treatment ser-
vices.
How were the data analysed?
All information was entered by a programme
secretary into a central records notebook.
The secretary calculated the percentage of
referrals from each referral source for each
programme, and categorised waiting times
for the different types of treatment services
offered.
What did they find out?
For the downtown PSU programme, the
greatest number of clients (37 percent) were
referred by the local emergency department.
However, the emergency department tended
not to make referrals to outlying clinics, even
for clients who lived in these regions. Most
referrals from outlying clinics came from fam-
ily members or were self-referrals. The out-
lying PSU programmes overlapped consid-
erably with the downtown programmes, but
tended to have shorter waiting lists.
What did they do with this information?
Researchers concluded that more education
of emergency department staff about the
outlying PSU programmes (including shorter
waiting lists) was warranted. They instituted
a brochure campaign and a series of presen-
tations at emergency department staff meet-
ings to accomplish this goal.
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Its your turn
Put the information from this workbook to
use for your own setting. Complete these
exercises below.
Remember to use the information from
Workbooks 1 and 2 to help you complete a
full evaluation plan. Review that information
now, if you have not already done so.
1 Apply your knowledge. Write down two
relevant examples of coverage questions
and two examples of process questions
for your own setting or treatment network.
Example: What is the average length
of treatment for cocaine users vs.
Opioid users?
1) ____________________________
______________________________
2) ____________________________
______________________________
3) ____________________________
______________________________
4) ____________________________
______________________________
Decide the most important question(s) to
pursue in the evaluation (see Workbook
1 for guidance on how to do this).
2 Determine whether your setting has an
information and/or data analysis system
that routinely generates basic informa-
tion on clients, services and discharge
circumstances. This system could be
computer-based or based on paper
records. These records may be espe-
cially useful sources of data for your
process evaluation.
3 Using the information provided in this
workbook, make the following deci-
sions:
Decide what method you will use to col-
lect the data. Review the information in
this workbook, and Workbook 1, to
help you decide. For residential
programmes, include number of days in
residence. For non-residential services,
include the number of sessions at-
tended, and the number of appoint-
ments missed.
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4 You will need to prepare an introductory
letter and consent form that explains the
purpose of your study (even for record
reviews). Review Section 1A of Work-
book 2, entitled, “Manage Ethical Issues”,
for more information about the important
topic of participants' rights in evaluation
research.
In general, all participants should be asked
permission ahead of time before being
enrolled in the study. When you do this,
you should explain the purpose, nature,
and time involved in their participation. No
person should be forced or coerced to
participate in the study.
The standard practice is to have each
participant sign a consent form, which:
• describes the purpose and methods of
the study
• explains what they will need to do if
they participate
• explains that participation is voluntary
In some cases, existing databases may be
accessed without formal permission from
clients. Consult local advisors for guide-
lines in your institution and/or region.
Using the information and examples pro-
vided in Workbook 2, section 1A, write
your own introductory letter and consent
form.
5 Run a pilot test of your evaluation mea-
surement and procedures on 10-15 pa-
tients to ensure that everything runs
smoothly. Review section 1C of Work-
book 2 entitled “Conduct a Pilot Test”
for specific information about how to do
this. In general, pilot tests assess these
questions:
• Do the questions provide useful infor-
mation?
• Can the questions be administered
properly? For example, are they too
long or too complicated to be filled out
properly?
• Can the information be easily managed
by people responsible for tallying the
data?
• Does other information need to be
collected?
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In this workbook, we have outlined the ba-
sic principles and practices of process evalu-
ation of PSU services and systems. With pro-
cess evaluations, you are concerned with
how people enter into your treatment ser-
vice or system and what happens to them
once there. The specific questions and issues
that you explore will be dependent on your
unique circumstances and cultural context.
These questions and issues must be clearly
identified through the evaluation planning
phase as described in Workbook 1.
In undertaking process evaluation, it is es-
sential that you pay close attention to the prin-
ciples and practices of data collection and
analysis as outlined in Workbook 2. Trade-
offs have to be made as to the rigour with
which you collect and analyse information to
answer your evaluation questions, and the
resources you have available. You must strive
to achieve the best possible information with
the time and resources available to you. You
must carefully document the limitations of
your findings and conclusions. With these
principles in mind, you will be able to under-
take practical and useful process evaluation
of your treatment service or system.
After completing your treatment evaluation,
you want to ensure that your results are put
to practical use. One way is to report your
results in written form (described in Work-
book 2, Step 4). It is equally important, how-
ever, to explore what the results mean for
your programme. Do changes need to hap-
pen? If so, what is the best way to accom-
plish this?
Return to the expected user(s) of the research
with specific recommendations based on your
results. List your recommendations, link them
logically to your results, and suggest a pe-
riod for implementation of changes. The ex-
amples below illustrate this technique.
Based on the finding that over 60 percent of
clients are waiting more than 2 months for an
initial appointment, we recommend that the
programme convert to a group assessment
format that uses paper and pencil question-
naires as an initial screening tool.
Remember, process evaluations are a criti-
cal step to better understanding the day to
day functioning of your PSU services. It is
important to use the information that process
evaluations provide to redirect treatment ser-
vices. Through careful examination of your
results, you can develop helpful recommen-
dations for your programme. In this way, you
can take important steps to create a “healthy
culture for evaluation” within your
organisation.
Conclusion
and a practical
recommendation
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Appendix
Psychoactive substance use
Substance
Used in past
12 months
(1= Yes / 2= No)
Number of days
used in past 90
(Days)
Average quantity
per day of use in
past 90 days*
Use currently a
problem?
(1= Yes / 2 = No)
* It may be difficult to quantify the exact amount for certain substances. Indirect estimates can be made from the number of times per day a substance is injected, inhaled, snorted, or smoked.
Alcohol (beer, liquor, wine)
Cocaine/ crack/ coke
Amphetamines/ other stimulants
Cannabis (hash, weed, grass, pot, marijuana)
Benzodiazepines
Barbiturates
Heroin/ opium
Prescription opioids
Over-the-counter codeine preparations
Hallucinogens
Glue/ other inhalants
Tobacco
Other psychoactive substances
Instruments in Appendix 1 are adapted
from a data collection protocol for treat-
ment process and outcome monitoring be-
ing developed by the Addiction Research
Foundation, Ontario, Canada. Information
about these instruments can be obtained
from: Addiction Research Foundation, 100
Collip Circle, Suite 200, London, Ontario,
Canada, N6G 4X8.
In addition to considering these instru-
ments, a review of the ARF Outcome
Measures Directory (undated) is highly
recommended. This Directory contains
many potentially useful instruments for
process evaluation and discusses reli-
ability, validity, and practical issues in
administration.
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i) During the past 90 days, on how many days did you inject
any kind of psychoactive substance?
ii) Have you ever shared a needle, syringe, cooker/spoon or
cotton/filter with anyone at any time in your life?
If Yes, during the past 90 days, on how many days did you share
a needle, syringe, cooker/spoon or cotton/filter with anyone?
    During the past 90 days, with how many people have you
shared?
Risk behaviour
1 Thinking about your use of psychoactive substances, have you:
Never injected Injected prior to one year ago
Injected in the last 12 months Unknown
If ever injected, answer the following questions:
Health and correctional service utilisation
1 Thinking about physical health problems, during the past 90 days, how many:
• times have you had to go to the emergency room times
• nights total did you spend in the hospital nights
• times did you have an outpatient surgical procedure times
• times did you see a doctor in an office or outpatient clinic times
2 a) Thinking about mental health problems, during the past 90 days, how many:
• times have you had to go to the emergency room times
• nights total did you spend in the hospital nights
• times did you see a doctor in an office or outpatient clinic times
days
days
people
2 How often do you use condoms with your sexual partner or partners?
Never Sometimes Always
During the past 90 days, how many times have you had
unprotected sex?
times
3 During the past 90 days, on how many days have you driven
a motor vehicle or used a machine at the workplace while
under the influence of alcohol or other psychoactive sub-
stances?
days
Yes No No response
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b)Are you currently in any type of treatment or counselling for mental or emotional
problems?
3 Over the last 90 days, how many days have you received alcohol or substance use
treatment at the following places?
• a hospital overnight for withdrawal or related problems days
• an inpatient substance use treatment facility (3 -90 days) days
• a long-term (3 to 12 months) residential program or
therapeutic community for substance use disorder treatment days
• a methadone or other opioid treatment program days
• an assessment or outpatient substance use treatment facility sessions
• a mental health centre or facility as an outpatient sessions
• an employee assistance program sessions
• a family and/or marital counselling service sessions
• an emergency room days
• a private doctor’s office visits
• a prison or jail days
• some other place (please describe __________________ ) days
Yes No No response
4 a) How many self-help meetings, (e.g., AA, NA, ACOA)
have you attended for your substance use problem in the past
90 days?
b) How many self-help meetings have you attended for is-
sues other than substance use problems in the past 90 days?
meetings
meetings
5 a) During the past 90 days, how many days have you been on probation or parole or
been in jail or custody?
• Probation days
• Parole days
• Jail/prison/closed custody days
• Open custody days
b) During the past 90 days, how many times have you been
charged for breaking the law (please do not count minor traffic
violations)?
times
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Were you charged with:
• driving while impaired
• drunkenness or other liquor law violation
• possession, distribution, or sale of illegal substances
• sexual assault
• theft (including B&E, theft over and theft under)
• violence against family or others
• major crime
• Other (please describe __________________________  )
Please
check if
Yes
# of charges
in the last
90 days
Client Motivation
Treatment entry questionnaire:
Use the following scale to make your ratings
INSTRUCTIONS:
Please indicate
whether you agree
or disagree with
each of the
following
statements by
placing the
number that best
reflects your own
personal opinion
in the blank
provided.
Remember, there
are no right or
wrong answers,
and your
responses are
completely
confidential.
Strongly
Disagree
Strongly
Agree
1 If I remain in treatment it will probably be because I feel that
it’s the best way to help myself.
2 I plan to go through with a treatment program because I’ll hate
myself if I don’t get my habit under control.
3 I have agreed to follow a treatment program because I was
referred for treatment by the legal system.
4 I plan to go through with a treatment program because it’s a
challenge to learn how to live without misusing psychoactive
substances.
5 I plan to go through with a treatment program because my
friends and family won't approve of me unless I do.
6 Being in a program is a way for me to avoid getting punished
for my behaviours.
7 I decided to enter a program because I was interested in get-
ting help.
8 I decided to enter a program because I won't like myself very
much unless my substance use problem is under control.
9 I had no choice about coming into a treatment program.
10 I plan to go through with the treatment program because hav-
ing a substance use problem makes it hard for me to do things
I want to do.
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
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11 My family made sure that I entered a program.
12 If I remain in treatment it will probably be because others will
be angry with me if I don’t.
13 I decided to enter a program because I really want to make
some changes in my life.
14 I have agreed to follow a program because I want others to see
that I am really trying deal with my habit.
15 I plan to go through with treatment because I’ll be ashamed of
myself if I don’t.
16 I decided to enter this program because no one other than my-
self can change the way I am.
17 The reason I am in treatment is because other people have
pressured me into being here.
18 If I remain in treatment it will probably be because I’ll feel like
a failure if I don’t.
19 I plan to go through with a treatment program because I’ll get
into trouble with the law if I don’t remain in treatment.
20 I plan to go through with a treatment program because I have
freely chosen to be here.
21 If I remain in treatment it will probably be because people will
think I’m a weak person if I don’t.
22 I decided to enter a program because it feels important for me
personally to deal with my substance use problem.
23 I have agreed to follow a treatment program because I’ll get in trouble
with my friends and family if I don’t follow all the guidelines.
24 I plan to go through with a treatment program because not hav-
ing problems due to substances is a choice I really want to make.
25 My friends strongly pressured me to come into a program.
26 If I remain in treatment it will probably be because I’ll feel very
bad about myself if I don’t.
27 I have agreed to follow the procedures of the treatment program
because it’s a personal challenge for me to deal with my problem.
28 I have agreed to follow a treatment program because I was
pressured to come.
29 I decided to enter a program because people will like me better
when I have dealt with my habit.
30 I was basically forced into a treatment program.
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
1 2 3 4 5 6 7
Strongly
Disagree
Strongly
Agree
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Whereas the prior cases in this workbook
presented evaluations related to either cov-
erage or process, the following two cases
incorporate questions related to both cover-
age and process.
The first case example describes the evalua-
tion of an alcohol home detoxification ser-
vice in the United Kingdom. The evaluator
wanted to know about coverage issues, such
as demographic and clinical characteristics
of clients, and also wanted to know about
process issues, such as number of completed
detoxifications, client workloads for nurse
practitioners, and average mileage accrued
while driving to see clients. Aspects of cost
evaluation (Workbook 5) and client satisfac-
tion evaluation (Workbook 6) also were in-
cluded. Of note, the case author/evaluator
describes procedures for developing a new
computer-based client tracking system. With
no prior experience with the software, this
task was completed in less than 24 hours.
Evaluation efforts were worthwhile, as re-
sults were used to increase awareness of the
detoxification programme and justify further
funding.
The second case describes preliminary re-
sults from a Swiss evaluation of the medical
prescription of narcotics for heroin-depen-
dent people. Evaluators used a variety of data
collection methods, including treatment
programme records, patient interviews, and
third party information. They assessed cov-
erage issues such as participant characteris-
tics, and also process issues such as adher-
ence to treatment and safety of the narcotic
prescriptions.
It is noteworthy that neither of these cases
focused upon treatment efficacy or outcome.
Rather, the main questions centered around
the process of treatment itself. Evaluations
of this type are important to establish confi-
dence that treatment is serving the intended
clients and being conducted in the desired
manner.
Comments about
case examples
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The author alone is
responsible for the
views expressed in this
case example.
Process evaluation of alcohol home
detoxification and assessment
by David B. Cooper, RN, FETC
Parkholme, Ashreigney, Chulmleigh, Devon EX18 7LY
Halls Mill Lane, Bradiford, Barnstaple, Devon EX31 4DP
Telephone/Facsmilie +44.0.1769.520 469
Who was asking the
question(s) and why
did they want the
information?
Alcohol home detoxification and assessment
(AHDA) (or community detoxification) whilst
not new, is a recent, expanding development
in community service provision. A fundamen-
tal concept is that of thorough assessment of
those individuals referred for treatment dur-
ing alcohol withdrawal. An holistic and eclec-
tic assessment addresses two key questions
(Stockwell 1987):
• Is there a need for any medication to al-
leviate withdrawal symptoms?
IF YES:
• Are there any reasons for not keeping the
individual within the home environment for
detoxification?
Formally, the role of developing AHDA
services lay with the statutory sector (Na-
tional Health Service - NHS). However,
over the last seven years, specialist volun-
tary sector services have looked towards
employing a qualified nurse(s) to develop
and evaluate AHDA to:
• compliment the existing counselling ser-
vices;
• provide an alternative to inpatient care;
• ensure that those who need inpatient care
during alcohol withdrawal receive the
appropriate intervention; those who need
clinical supervision but do not require in-
tensive inpatient supervision during alco-
hol withdrawal can do so within the home
environment safely; and of significant im-
portance, those who do not need medi-
cation or supervision during alcohol with-
drawal receive the right level of
intervention from appropriate sources
without inappropriate use of limited re-
sources.
This case study looks at the processes of
evaluation used by a voluntary sector ser-
vice (Suffolk Community Alcohol Service
(SCAS)) during a three year AHDA pilot
project (January 1994-December 1996).
The case study will also briefly discuss the
value of the Advantage SM database in
AHDA evaluation (see Appendix 7).
Case example of a
process evaluation
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About SCAS
SCAS functions as a central source of infor-
mation, advice, training and education, coun-
selling, organisation and collaborative work
in the field of alcohol use throughout the
county of Suffolk. The predominant part of
the service facility is in East Suffolk. It be-
came apparent in 1992 that during the six
years of operation, SCAS had seen an in-
crease of 296% in requests for help, advice
and intervention. One consequence of the
developing referral rate was that agency staff
were increasingly being called upon to pro-
vide an alternative to inpatient detoxification
for problem drinkers requiring short-term,
intensive, specialist and clinical intervention
(Cooper, 1992). In response to the increase
in referrals, and the identified gap in service
provision, SCAS proposed to establish a
three year project to develop and assess the
need for an alternative to inpatient detoxifi-
cation (i.e., a AHDA service).
It was suggested that a Registered Nurse,
specialising in home detoxification, could pro-
vide a cost effective alternative to in-patient
care, and that the service would go some way
towards meeting the present shortfall in ser-
vice provision for problem drinkers in East
Suffolk. A funding proposal was submitted,
and approved, for joint social services and
health authority funding for the AHDA East
Suffolk project. SCAS provided, and man-
aged, the AHDA project. The initiative came
from the director, Mary Jeffries.
The alcohol home detoxification and assess-
ment (AHAD) project accepted referral from
any source, including self. The primary crite-
ria for referral were that the individual re-
quired detoxification. The hypothesis was
that:
• many individuals requiring detoxification
were admitted to hospital unnecessarily
for clinical supervision during the with-
drawal period;
• those who were detoxicated at home
were more likely to complete the detoxi-
fication;
• those who were detoxicated at home
were satisfied with the service provided;
• many of the referrals received did not re-
quire inpatient or home detoxification.
• evaluation of the outcome of each refer-
ral and intervention would give some in-
dication of the impact on other services,
in particular the SCAS counselling ser-
vice;
• a period of 6, 12 and 24 month follow-
up would be beneficial in terms of service
development. However, it was agreed that
this information would not have any sig-
nificant bearing on the effectiveness of al-
cohol home detoxification. It is generally
acknowledged that other interventions
would have a significant impact on long
term outcome and that clinically super-
vised detoxification is a small (rather than
the whole) part of any treatment package
(Cooper, 1994).
What resources were
needed to collect and
interpret the
information?
In order to assess the effectiveness of the
service, SCAS needed to collect data ca-
pable of providing some answers to the pre-
viously mentioned issues and questions. A
nurse practitioner (Registered Nurse) was
appointed for the project whose areas of
responsibility were:
• assessment and provision of clinical care
to the client group;
• evaluation of the project; and,
• communication and public relations dur-
ing project development.
It was agreed that two forms of data collec-
tion were required: (a) the means to collect
individual data from the client, supporter and
other professional and services involved in
the care on an individual referral basis; (b)
the means to bring together the data for pur-
poses of collation and evaluation.
33Workbook 4  •  Process Evaluations
WHO/MSD/MSB 00.2e
It was intended that the Nurse Practitioner
(NP) would collect the data on an ongoing
basis. The NP would have the support of a
part-time (20 hours per week) Administra-
tive / Research Assistant. At the end of the
project, three months had been set aside for
the NP to analyse and report the data. Data
was in fact collected by the NP, but not sys-
tematically collated; hence, the subsequent
hiring of this author to collage, analyse and
report available data which was then recycled
into the SCAS report quoted.
The work took eight very long working weeks
(seven days per week)! It still is believed, as
was recommended in the initial proposal for
SCAS funding (prepared by this author), that
the Nurse Practitioner and one part-time (20
hours per week) Administrative / Research
Assistant and a computer with a compatible
programme, could undertake this project.
How were the data
collected?
Individual client record
The Individual Client Record (appendix 1)
was a hand-completed from, which was the
first stage in the tracking system of all refer-
rals to the project. Each entry corresponded
to the database entry used for the collation
and evaluation of the data. As a numerical
system was felt to be the most appropriate,
a separate score sheet was produced as an
aid to memory, on which the database would
be designed (see appendix 2 for detailed
description of coding).
Information recorded on the AHDA indi-
vidual client record was entered onto the
Access database manually using the AHDA
code sheet to change responses into a nu-
merical equivalent. For example, the source
of referral could be a general practitioner
(GP), coded as '1,' or a community psychi-
atric nurse (CPN), coded as '4.' A separate
record of actual client contact was recorded
in a diary and hand collated to allow for
cross-reference.
Tracking system
The major part of the information required
to monitor the effectiveness of the project
was the tracking system. It was decided to
use the Access database system, which forms
part of the Microsoft Office Professional
software package.
Client awareness
It was agreed that both the client and sup-
porter should be fully informed of the pur-
pose of the project, and that as part of the
assessment process a full explanation of the
purpose of the project would be given. As-
surances relating to confidentiality of infor-
mation collected for evaluation were made.
It was explained that a refusal to allow such
information to be passed on would NOT
exclude the individual from treatment. The
opportunity to decline or withdraw permis-
sion was also given at any time. No one re-
fused permission.
Data collection
The nurse practitioner collected data from
various sources. These data, together with
the data from the client and supporter satis-
faction questionnaire and GP questionnaire,
was hand recorded onto the database by the
author. Using a combination of computer
aided collation, and simple hand analysis, a
crude picture could be drawn as to the ef-
fectiveness of the AHDA project.
Client and supporter
satisfaction scale
Recognised client and supporter satisfaction
scales are already available and have estab-
lished validity (Stockwell et al, 1990 - Ap-
pendix 3 & 4). Some minor modifications to
replace the sliding scale with a numerical sys-
tem for ease of evaluation were used.
Home detoxification follow-up: The Home
Detoxification Follow-up from consisted of
five active parts (appendix 5). The follow-
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up agreed upon for the 6, 12, 24 months fol-
lowing detoxification was not designed to
assess the success of the detoxification it-
self. It was introduced as an attempt to see if
interventions following detoxification pro-
duced any significant changes in drinking
pattern. It was merely a “look and see”
exercise which may or may not assist in fu-
ture service planning.
The data collected on the client (appendix
3) and supporter (appendix 4) satisfaction
scale was first entered on a specially designed
Access database using the numerical coding
on the forms. The select button was used to
draw out the relevant section of data which
was hand collated using percentage and
simple numerical comparison. The sections
allowing for free comment were recorded in
full with some minor discussion of content.
In order to balance out consistently high lev-
els of satisfaction recorded in different set-
tings, the neutral responses were regarded
as possibly negative and therefore, positive
ratings of below 75% was regarded as cause
for concern (Pelletier 1985).
The scale would be applied only to those who
completed a detoxification in the home. It was
acknowledged that during a three-year pe-
riod some individuals might require more than
one detoxification. Therefore, only one ques-
tionnaire would be sent to the client and the
supporter. All questionnaires would be sent
at the end of the project in three waves.
Wave 1: A pre-coded questionnaire was
sent individually by the nurse practitioner to
each client and supporter. For those who had
received more than one detoxification, a para-
graph in the letter requested that the individual
base the response on the last detoxification
occasion. The letter also reaffirmed the pur-
pose of the project and thanked the individual
for his or her assistance. A stamped ad-
dressed envelope was included - addressed
to the nurse practitioner. Returned question-
naires were logged on the 'Individual Cli-
ent Record' (appendix 1). Those individuals
refusing to complete the from were logged
accordingly and no further contact was made.
Wave 2: Two weeks after the closing date
for return of Wave 1 questionnaire, a sec-
ond questionnaire was sent to non-respon-
dents. Again the accompanying letter re-
freshed the reader to the purpose of the
project and asked for assistance. This letter
carried a paragraph that stated that as part
of the survey process those who had not re-
sponded by the deadline date would receive
a telephone call from the nurse practitioner.
If the client or supporter did not wish to re-
ceive such contact, it was requested s/he re-
turned the blank form in the reply paid enve-
lope and no further contact would be made.
The 'Individual Client Record' (appendix
1) was updated.
Wave 3: Two weeks following the dead-
line, non-respondents received a follow-up
call from the nurse practitioner. This was un-
dertaken in a low-key fashion. It was felt im-
portant that the individual did not feel pres-
sured. The approach was that if there was
something wrong, it was important to us. The
'Individual Client Record' (appendix 1) was
updated, and completed.
The home detoxification
general practitioner form
The Home Detoxification General Practitio-
ner Questionnaire (appendix 6) was origi-
nally designed by Kaner & Masterson
(1996) and was used with minor adaptations
for local needs. Using a separate Access
database, and the YES = 1, NO =2 numeri-
cal system, it was possible to hand draw in-
formation from the computer for numerical
and percentage analysis. The free comments
were reproduced in full. The questionnaire
was sent to every GP in the East Suffolk area
and consisted primarily of Yes or No type
responses (later converted to numerical
equivalent for ease of collation).
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How were the data
analysed?
Operational activity
One area of interest to the service managers
was how many actual clinical working hours
were available to the nurse practitioner. From
the gross operational days of the project, the
following were deducted to produce a “clini-
cal operational time”: annual leave; bank
holidays; sickness; training sessions attended
as a student; training sessions given to oth-
ers; interim report writing; crown court at-
tendance; clinical supervision; professional
practice and team meetings; management
supervision.
Most of this was taken from time sheets, the
nurse practitioner’s personal profile and di-
ary, and the clinical supervisor. Compilation
was by pen and paper. By deduction of this
data to establish a “clinical operational
time,” it was possible to ascertain how many
individuals received assessment, and detoxi-
fication supervision within the clinical opera-
tional time frame.
Mileage
East Suffolk covers a wide area. As such, it
was felt to be of value if some emphasis was
given to travel time as this does have an ef-
fect on the number of client contacts. This
was completed at the end of the project by
using the official monthly mileage returns.
From these it was possible to establish: the
total mileage; the average mileage per day;
the longest day trip; the training mileage and
the average trip.
Client contact
From the individual clinical records it was
possible to establish the number of individual
client contacts (how many times was an in-
dividual seen in total) made during the project.
From this it was possible to calculate the
average daily, weekly and monthly contact
rate. Unfortunately this information only in-
cluded direct client contact and not indirect
contact with the supporter, the referring
agent, by telephone or activities involving mail,
etc. This was a shortcoming in the planning
process of evaluation.
Cost
A primary concern to all funders and service
providers is “How much does it cost?” and
“Is it cost effective?”. Interestingly, it was not
possible to establish exactly how much it
would cost to keep a patient for a 24-hour
period on an acute mental health ward, this
being the usual area for in-patient detoxifi-
cation in the UK from the statutory sector -
NHS. So it was agreed to use the bed occu-
pancy figure established in the project pro-
posal, on which the 3 year funding was based,
and compare this with the total funding cost
as at the project proposal, thus disallowing
any built-in inflationary costs (Cooper, 1992).
Using the total completed detoxifications and
the average duration of the home detoxifica-
tion, with the average in-patient detoxifica-
tion suggested by Cooper (1985, 1988), it
was possible to provide a daily cost, and an
individual client cost, for both in-patient and
home detoxification and compare these.
Tracking system
As mentioned earlier, it was decided to use
the Access database system, which forms
part of the Microsoft Office Professional
software package, because the design tech-
niques were easy to follow. Individual fields
were created on the database to correspond
with the entries on the “Individual Client
Record.”
Whilst it is possible to do some specific data
collection with this package and with the sis-
ter program Excel, computer competence
was limited in such techniques. The Access
database allowed for simple numerical data
entry, and by using the “button” filter system,
supported by hand calculation, to bring to-
gether the essential data, it was possible to
effectively evaluate the collated data. The
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author, with no previous experience of the
system, developed the database within 24
hours. Using this system, the following data
were analysed:
• how many collective referrals were re-
ceived;
• who made the referral;
• client gender;
• age range of clients;
• employment status of the clients;
• number of referral occasions the individual
had;
• number of referrals received weekly and
any increase or decrease;
• number of referrals received monthly and
any increase or decrease;
• number of the referrals leading to full as-
sessment;
• number of assessments undertaken
weekly;
• number of assessments undertaken
monthly;
• reasons for no assessment;
• number of referrals leading to detoxifica-
tion;
• number of completed detoxifications com-
mencing weekly;
• number of completed detoxifications com-
mencing monthly;
• number of completed detoxifications;
• how long did (the completed) detoxifica-
tion last and how much did it cost;
• reasons for no-completion of detoxifica-
tion;
• due dates of the 6, 12 and 24 month fol-
low-ups and completed or reasons why
they had not been completed;
• completion dates for the client and sup-
porter satisfaction scales for Waves, 1, 2
and 3, how many were completed, and
at what wave did we get the response;
• the outcome of each referral or reason
why we did not have a known outcome;
• the impact on other services as a result of
referrals, assessment or detoxification;
• additional space was provided for any
notes for information considered of value.
Client and supporter
satisfaction scales
The client and supporter satisfaction scale
data were compiled along with data from the
Individual Client Record (e.g., age), and
the nurse practitioners clinical notes (e.g.,
supporter relationship and sex), using a sepa-
rate Access database within Microsoft Of-
fice Professional. Using a numerical system,
responses to each questionnaire was entered
on the database.
What did they find out?
The AHDA project had a total of 650 op-
erational days (130 working weeks) of which
480 days (74%) were available for clinical
operation. Forty-nine days (7.5%) were
spent on clinical and managerial supervision
and team meetings and 25 days (4%) divided
evenly on education given and received by
the Nurse Practitioner (Ayers, 1997).
Mileage accounted for some 19,334 miles,
a mean of 36.8 miles per day, for the 27
months of available data. Given the size of
the area, this figure was considered reason-
able (Ayers, 1997).
As noted above, it was not possible to ob-
tain an accurate cost for one, 24 hour, inpa-
tient stay from the acute mental health unit.
However, by using an agreed upon 1993 fig-
ure (£173 per day), it was possible to pro-
vide some crude cost comparisons. Of the
79 completed home detoxification stays av-
eraging eight days, the mean cost per client
was £1,474.93 or £184.36 per day. The
results suggested that AHDA was slightly
more expensive than the 1993 cost of £173
per day for in-patient detoxification. How-
ever, in terms of effectiveness, data collected
enabled the project to claim:
• that 90% of those individuals who required
medically supervised detoxification did not
progress to in-patient care. The figures
available for inpatient bed occupancy
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during the AHDA project indicated a
gradual decline in demand;
• that less than 40% of those referred for
detoxification, required a medically super-
vised detoxification;
• that home detoxification was more likely
to be completed in comparison to inpa-
tient detoxification;
• the average detoxification at home lasted
8 days in comparison to 12 days in-pa-
tient detoxification (Ayers, 1997).
The true value of any service lies in the satis-
faction of the client and supporter. Forty-five
(57%) of the 79 individuals who completed
detoxification responded to the client satis-
faction scale. Twenty-eight (35%) of sup-
porters responded to the supporter satisfac-
tion scale. The results suggested that overall,
78% of clients and supporters were satisfied
with the home detoxification. Whilst there
were some minimal comments in terms of
over-or-under sedation, the level of dissat-
isfaction with medication was minimal. In
general, it was the supporter who felt less
supported and it has been agreed that infor-
mation given to the supporter needs to be
more overt in any future service development
(Ayers, 1997).
The home detoxification follow-up ques-
tionnaire had some design faults. For ex-
ample, a future questionnaire would need
clarification that “supporter” referred to
other professional or agency and not the
family member or friend. The form also
failed to account for changes in the client
treatment goal, (e.g., whilst the individual
may have stated total abstinence as the
goal, during the 12 or 24 months, s/he may
have commenced drinking at a socially
acceptable level). However, the response
on the questionnaire could not distinguish
between trouble-free alcohol consumption
and relapse.
These difficulties not withstanding, the data
suggested that those individuals who had
completed detoxification at home, and had
follow-up counselling from a SCAS coun-
sellor appeared to maintain their chosen treat-
ment goal longer than those with other pro-
fessional support, or no intervention.
However, this area would need a more sci-
entific analysis before any significant claims
could be made.
Seventy-seven percent (n=14) of rural and
85% (n=23) urban practices responded to
the GP questionnaire, involving 47% (n=33)
rural and 61% (n=75) individual GP’s. Over-
all, 58% (n=60) had reported carrying out
detoxifications at home, of which 45 GP’s
were in rural practices. Sixty percent of re-
spondents had received a visit from the nurse
practitioner of which 46% had referred one
or more client to the nurse practitioner in
comparison to the 20% from those GP’s who
had not received a nurse practitioner visit
(Ayers, 1997).
There were many accompanying letters and
calls offering support for the project, and
requesting personal contact. The question-
naire also acted as additional promotional
material for the service project, prompting
an increase in referrals from those who had
previously not used the service. The data
seemed to suggest that those GP’s were the
client outcome had been successful in terms
of completion and reduced GP contact were
more inclined to feel the value of the service
in comparison to those GP’s who had an
unsuccessful detoxification referral. Overall,
67% of GP’s were satisfied with the service.
From the “comment” received, the informa-
tion suggested a need for a concerted train-
ing programme for GP’s in terms of the na-
ture of alcohol related problems, and client
expectation. Some GP’s quoted a lack of
motivation from the client, pressure of work
and time, cost implications, and lack of
knowledge as reasons for not engaging this
client group.
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How were the results
used?
It is not possible nor practical to detail all the
results from the AHDA project. Much of the
data is confidential forming part of a report
to the management committee. In today’s
highly competitive market within the UK
NHS, such data is a valuable source of sup-
port needed to secure funding for subsequent
next years.
As a result of the service evaluation some
areas involving service development have
become clear, and include:
• An increased level of public relations and
training activity with the GP. Of the 267
referrals received, the Nurse Practitioner
assessed 220 individuals, of which 117
were first time referral and 38 second. 87
were from GP’s and 72 from the SCAS
counselling service (Ayers, 1997). Many
of the referrals would have been more
appropriate, had the referring agent had
more knowledge in the assessment of
clinical intervention during detoxification.
It is possible, that the large amount of re-
ferrals from the GP included some that
were a means of side stepping the local
hospital procedure.
• Waiting time was felt to be reasonable
with 40% of individuals being seen within
48 hours. Some modification to the initial
assessment intervention has been made
by SCAS to improve on this figure.
• The AHDA has been funded for a further
18 months, whilst a review of all service
provision for substance misusers in Suf-
folk takes place. The project will continue
with an ongoing evaluation.
• More attention to the supporters’ indi-
vidual needs will be given on each visiting
occasion.
• All referrals to the AHDA project will have
an initial telephone inquiry to aid filtering
of inappropriate referrals. A full assess-
ment would only be completed if there
were strong indications that home detoxi-
fication was indicated. A trained admin-
istrative assistant, to free up the Nurse
Practitioner’s time would complete the
follow-up questionnaire. The Nurse Prac-
titioner would increase the role of con-
sultant supporting and encouraging pro-
fessionals wishing to supervise home
detoxification. All clients would receive
at least one daily visit, with clear written
justification should this not be appropri-
ate. A client checklist at salient points in
detoxification, and care plan, would be
maintained at the client home. More at-
tention to the client’s perceived level of
comfort during detoxification would be
given.
• A GP satisfaction questionnaire to be
completed following each detoxification
may be introduced.
This case study is believed to be representa-
tive of the type of information one could ex-
pect from a small, voluntary sector service.
The SCAS evaluation aimed to provide suf-
ficient information to satisfy the funding agent
with a view to establishing continued finan-
cial support. It is sufficient to expect one or
two members of staff to develop and main-
tain this information whilst undertaking clini-
cal duties.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three posi-
tive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
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Case example appendix 1
AHDA Individual Client Record
Note ALL sections MUST be completed
File Complete? Yes No
File Dead? Yes No
Code
HEADING ENTRY HEADING ENTRY
Source CssOcc1
Sex CssOcc1
Age DateCssOcc1
Employment Status Occ1Rtn
Referral Occ1RtnDate
WkNoRef State CssOcc1
MthNoRef CssOcc2
Assessed DateCssOcc2
AssessDate Occ2Rtn
WkNoAss Occ2RtnDate
MthNoAss State CssOcc2
1 State CssOcc3
Detoxed DateCssOcc3
DetoxDate Occ3Rtn
WkNoDtx Occ3RtnDate
MthNoDtx State CssOcc3
DetoxEnd Outcome
DetoxLength SssOcc1
2 State DateSssOcc1
FUDue6/12 SupOcc1Rtn
FUDone6/12 SupOcc1RtnDate
DateFU6/12 State SssOcc1
State 6/12 SssOcc2
FUDue12/12 DateSssOcc2
FUDone12/12 SupOcc2Rtn
DateFU12/12 SupOcc2RtnDate
State 12/12 State SssOcc2
FUDue24/24 SssOcc3
FUDone24/24 DateSssOcc3
DateFU24/24 SupOcc3Rtn
State 24/24 SupOcc3RtnDate
State SssOcc3
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HEADING MEANING CODE
Total Total number of referral occasions AutoNumber
Code Client Number Enter Client Number
Source Who made the referral 1 GP
2 SCAS Counsellor
3 Self
4 CPN
5 SHO’s
6 Relative/Partner
7 SSD (SW)
8 Probation
9 CDT
10 Age Concern
11 Employer
12 Psychiatrist
13 Registrar
14 Warden
15 General Hospital
20 Unknown
Episode Is this the 1st, 2nd, 3rd etc., referral Number each referral - 1, 2, 3, etc.,
Sex Client Gender 1 Male
2 Female
Age Clients Age Enter age
11 Unknown
Employment Status Employment Status 1 Employed
2 Unemployed,
3 Semi-retired
4 Retired,
5 Houseperson
6 Unknown
Referral Date Referral Received Enter Date
WkNoRef In what week number was the referral Enter week number
received, e.g., 1, 20, 52, etc.
MthNoRef In what month number was the referral Enter month number
received, e.g., 1, 6, 12, etc.
Assessed Was the client assessed? 1 Yes
2 No
3 N/A
AssessDate Date of assessment Enter Date
WkNoAss In what week number was the assessment Enter week number
received, e.g., 1, 20, 52, etc
MthNoAss In what month number was the assessment Enter month number
received, e.g., 1, 6, 12, etc.
1 State Why was the referral not assessed? State - use as few words as possible.
This may be coded when we get an idea of type
Detoxed Was the client detoxicated 1 Yes
2 No
3 N/A
Case example appendix 2
AHDA Code Sheet
Note ALL sections MUST be completed
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DetoxDate Date detoxication commenced Enter Date
WkNoDtx In what week number was the detox Enter week number
started, e.g., 1, 20, 52, etc
MthNoDtx In what month number was the detox Enter month number
started, e.g., 1, 6, 12, etc.
DetoxEnd Date detoxication ended Enter Date
Detoxlength For how many days did the detoxication last Enter Number of Days
2 State Why did you not detox the client State - use as few words as possible.
This may be coded when we get an idea of type
FUDue6/12 Date the 6 month follow-up due Enter Date
FUDone6/12 Has the 6-month follow-up completed? 1 Yes
2 No
3 N/A
DateFU6/12 Date the 6 month follow-up completed Enter Date
State 6/12 Why the 6 month follow up has not been State - use as few words as possible.
completed This may be coded when we get an idea of type
FUDue12/12 Date the 12 month follow-up due Enter Date
FUDone12/12 Has the 12-month follow-up completed? 1 Yes
2 No
3 N/A
DateFU12/12 Date the 12 month follow-up completed Enter Date
State 12/12 Why the 12 month follow up has not been State - use as few words as possible.
completed This may be coded when we get an idea of type
FUDue24/24 Date the 24 month follow-up due Enter Date
FUDone24/24 Has the 24-month follow-up completed? 1 Yes
2 No
3 N/A
DateFU24/24 Date the 24 month follow-up completed Enter Date
State 24/24 Why the 24 month follow up has not been State - use as few words as possible.
completed This may be coded when we get an idea of type
CssOcc1 Was the Client Satisfaction Scale sent 1 Yes
at first posting? 2 No
3 N/A
DateCssOcc1 Date the Client Satisfaction Scale was Enter Date
sent at first posting?
Occ1Rtn Was the Client Satisfaction Scale 1 Yes
completed at the first posting? 2 No
3 N/A
Occ1RtnDate Date the completed Client Satisfaction Enter Date
Scale was returned - first posting?
State CssOcc1 Why was the Client Satisfaction Scale State - use as few words as possible.
not completed at first posting? This may be coded when we get an idea of type
CssOcc2 Was the Client Satisfaction Scale sent 1 Yes
at second posting? 2 No
3 N/A
DateCssOcc2 Date the Client Satisfaction Scale was Enter Date
sent at second posting?
Occ2Rtn Was the Client Satisfaction Scale 1 Yes
completed at the second posting? 2 No
3 N/A
Occ2RtnDate Date the completed Client Satisfaction Enter Date
Scale was returned - second posting?
State CssOcc2 Why was the Client Satisfaction Scale State - use as few words as possible.
not completed at second posting? This may be coded when we get an idea of type
CssOcc3 Was the client contacted by telephone on 1 Yes
the third occasion following none return on 2 No
second occasion of Client Satisfaction Scale? 3 N/A
DateCssOcc3 What date did you make telephone contact? Enter Date
HEADING MEANING CODE
44 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2e
Occ3Rtn Did the client return the Client Satisfaction 1 Yes
Scale on the third occasion? 2 No
3 N/A
Occ3RtnDate What date was the Client Satisfaction Scale Enter Date
returned on the third occasion?
State CssOcc3 Why was the Client Satisfaction Scale State - use as few words as possible.
not completed at third posting? This may be coded when we get an idea of type
Outcome If the client was not detoxicated following 1 Inpatient care East Suffolk
assessment what happened? 2 Inpatient care outside
3 Inpatient rehab East Suffolk
4 Inpatient rehab outside
5 SCAS Counselling
6 No further action (NFA) Client request
7 Under care of CPN
8 Under care of CDT
9 Self referral - private care
10 Referred on CAT out of area
11 Unknown
12 Prison
SssOcc1 Was the Supporter Satisfaction Scale 1 Yes
sent at first posting? 2 No
3 N/A
DateSssOcc1 Date the Supporter Satisfaction Scale Enter Date
was sent at first posting?
SupOcc1Rtn Was the Supporter Satisfaction Scale 1 Yes
completed at the first posting? 2 No
3 N/A
SupOcc1RtnDate Date the completed Supporter Satisfaction Enter Date
Scale was returned - first posting?
State SssOcc1 Why was the Supporter Satisfaction Scale State - use as few words as possible.
not completed at first posting? This may be coded when we get an idea of type
SssOcc2 Was the Supporter Satisfaction Scale 1 Yes
sent at second posting? 2 No
3 N/A
DateSssOcc2 Date the Supporter Satisfaction Scale Enter Date
was sent at second posting?
SupOcc2Rtn Was the Supporter Satisfaction Scale 1 Yes
completed at the second posting? 2 No
3 N/A
SupOcc2RtnDate Date the completed Supporter Satisfaction Enter Date
Scale was returned - second posting?
State SssOcc2 Why was the Supporter Satisfaction Scale State - use as few words as possible.
not completed at second posting? This may be coded when we get an idea of type
SssOcc3 Was the supporter contacted by telephone 1 Yes
on the third occasion following none return 2 No
on second occasion of Supporter 3 N/A
Satisfaction Scale?
DateSssOcc3 What date did you make telephone contact? Enter Date
SupOcc3Rtn Did the supporter return the Supporter 1 Yes
Satisfaction Scale on the third occasion? 2 No
3 N/A
SupOcc3RtnDate What date was the Supporter Satisfaction Enter Date
Scale returned on the third occasion?
State SssOcc3 Why was the Supporter Satisfaction Scale State - use as few words as possible.
not completed at third posting? This may be coded when we get an idea of type
Notes General identifier Additional comment which may assist recall at a
later date - use as few words as possible.
This may be coded when we get an idea of type
HEADING MEANING CODE
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1 On the whole, how did you feel during your withdrawal from alcohol?
a) Very comfortable Very uncomfortable
b) Well supported Not well supported
c) Not craving for alcohol Craving for alcohol
d) Very calm Very anxious
e) In control of yourself Controlled by others
f) Very determined Not at all determined
g) Not at all tempted Very tempted to drink
h) Well informed Not at all well informed
2 Was the medication:
a) Too much Too little
b) Too long Too short
3 Were the visits from the nurse practitioner:
Too frequent Not frequent enough
4 During the home detoxification, how helpful were the following:
a) Support from your partner/friend Vital Unhelpful
b) Support from the nurse practitioner Vital Unhelpful
c) Support from other agency Vital Unhelpful
(Please state)
d) Support from your GP Vital Unhelpful
e) Visit from the nurse practitioner Vital Unhelpful
f) Drugs prescribed by your GP Vital Unhelpful
g) The physical check up Vital Unhelpful
h) The breath analyser Vital Unhelpful
5 What did you like most, or find the most helpful about the home detoxification procedure?
____________________________________________________________________________________________________
____________________________________________________________________________________________________
6 What did you like the least, or find the least helpful about the home detoxification procedure?
____________________________________________________________________________________________________
____________________________________________________________________________________________________
Thank you for completing this form. Please check that you have answered ALL the questions
Case example appendix 3
Confidential Client Satisfaction Scale
Date: _______________________________________ Code: ______________________________________________
These questions are designed to help us evaluate the detoxication procedure and its? effectiveness. Please circle ONE number,
per question, that is closest to your feelings.
Please answer ALL the questions
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
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Case example appendix 4
Confidential Supporter Satisfaction Scale
Date: _______________________________________ Code: ______________________________________________
These questions are designed to help us evaluate the detoxification procedure and its? effectiveness. Please circle ONE
number, per question, that is closest to your feelings.
Please answer ALL the questions
1 On the whole, how did you feel being involved in this home detoxification?
a) Very confident Not at all confident
b) Well supported Not well supported
c) Well informed Not well informed
d) Very calm Very anxious
e) In control Not in control
2 Were the visits from the nurse practitioner:
 Too frequent Not frequent enough
3 During the home detoxification, how helpful were the following:
a) The information sheet for relatives/friends Vital Unhelpful
b) Support from the nurse practitioner Vital Unhelpful
c) Support from other agency Vital Unhelpful
 (Please state)
d) Support from the GP Vital Unhelpful
e) Drugs prescribed by the GP Vital Unhelpful
f) The breath analyser checks Vital Unhelpful
g) Having a telephone number for immediate advice Vital Unhelpful
4 What did you find most helpful during this home detoxification?
____________________________________________________________________________________________________
____________________________________________________________________________________________________
5 What did you find the least helpful during this home detoxification?
____________________________________________________________________________________________________
____________________________________________________________________________________________________
Thank you for completing this form. Please check that you have answered ALL the questions
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
5 4 3 2 1
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1 On completion of home detoxification did the client (circle)
Attend SCAS for counselling
Attend a rehabilitation centre
Attend A.A. meetings
Receive any other support
If yes to .4. state: __________________________________
2 During the past (circle): 6 months 12 months 24 months - did the client
Have an Antabuse programme
Return to old pattern of drinking
If different drinking pattern, specify (circle):
a) Abstinence
b) Social Drinking
c) Controlled Drinking
d) Relapse
Relapse ++
3 Please indicate original resolve (circle):
a) Social Drinking
b) Controlled Drinking
c) Abstinence
4 Has the client kept to the original resolve (circle):
5 Drinking status on day of follow-up (state): ___________________________
Comments: ___________________________________________________________________________________________
____________________________________________________________________________________________________
Note: Y = Yes, N = No
Case example appendix 5
Home Detoxication Follow-up
Code: _______________________________________________________________________________________________
Date of Detoxification _______________________________________ Completed: ________________________________
Date of follow-up 6/12 12/12  24/24
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
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Have you ever carried out a home alcohol detoxification?
How many times have you been involved in such a procedure during the past year?
Did you carry out the detoxification in conjunction with another worker?
If yes, what profession were they (Nurse, CPN, Health Visitor, other - please specify)
_________________________________________________________________________
Did you engage the SCAS home detoxification nurse?
Did you feel satisfied with the outcome(s) of the detoxification(s)
Could you please say why?
_________________________________________________________________________
_________________________________________________________________________
What do you consider to be the main difficulty for a GP,
treating patients at home for their alcohol problem?
_________________________________________________________________________
_________________________________________________________________________
Would it make it much easier for you to undertake more home
based treatments for alcohol problems if:
There was somebody to monitor and visit the patient daily?
There were suggestions for appropriate medication?
There was guidance on the assessment of patients suitable for a home detoxification?
d) There was access to advice and information if uncertain about how to proceed?
There was information about follow-up counselling or support agencies for alcohol users?
f) Anything else?
_________________________________________________________________________
10. Would you be interested to receive a visit from the SCAS nurse practitioner?
Case example appendix 6
Home Detoxication General
Practitioner Questionnaire
General Practitioners Name: ______________________________________________________________________________
Practice Address: ______________________________________________________________________________________
______________________________________________________________________________________
Note: Please circle (Y = Yes, N = No) or state where appropriate
________________
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
N oYe s
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Case example appendix 7
AdvantageSM Software
AdvantageSM
The Alcohol Dependency System (ADS) and
the Drug Dependency System (DDS) were
comprehensive data collection systems pro-
duced by Miriam Healthcare, a private com-
pany established in 1992 (Yates, 1996).
These packages were capable of supplying
all the information outlined in this case study.
They also provide the clinical records, client
contact - direct and indirect - and various
assessment tools and scoring systems, and
produce reports in various formats including
pi-charts and graphs, pre-formatted letters.
Advantagesm is a much-improved version of
the ADS & DDS system. In comparison to
these software packages, this Windows 3:11
and 95 application offers significant improve-
ment in terms of a practical, user-friendly,
application. Without prior user knowledge of
the upgraded system, manual, instructions or
on-line support, the author quickly found his
way around the programme, and input data
(within the limitations of a demonstration
disc). Anyone with knowledge of Microsoft
applications such as MS Word, Access or
Excel would soon find their way around the
application.
Areas of significant improvement in terms of
ease of use and access included:
• Ability to quickly update the picklists.
• Change the system access, and access
level without compromising security.
• Screen-printing.
• Report printing, e.g., prescription-cost-
ing report.
• Prompts to save changes.
• The use of clear green “4” and red “X”
buttons.
• The database report
• Mail and contact addresses.
• Outcome measures.
• Graph with 3D application.
At the time of writing, the author understands
that the revised version will also include a
specific area to:
Record blood test results, e.g., blood alco-
hol concentration (BAC), Gamma GT, AST,
ALT, and MCV, etc. Urine test results, and
daily Breathalyser readings. Monitor and
record observations, e.g., blood pressure,
pulse, etc., and progress during detoxifica-
tion and any daily modification of drugs used
during detoxification.
The only area of concern was that included
in the list of drugs used for detoxification was
Heminevrin (chlormethiazole). The British
National Formulary (BNF 1995), and the
Committee on Safety of Medicines (1987)
advise against the use of this drug for alcohol
home detoxification.
One key problem to overcome with any soft-
ware package is to convince the end user
that the package is user friendly. The pack-
age was easy to use, and one quickly be-
came familiar with the controls and com-
mands. The picture, button and list support
was clear. It was easy to get in and out of
any area, e.g., from the client record file into
subsections of the file, without any real
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knowledge of the programme. The 'index file'
appearance is familiar to most end users, as
is the terminology used in each file and sub-
file. Just as important is the ability to print off
reports and charts quickly and effectively.
A key benefit of the software is that it could
easily be used on a laptop computer, and
taken into the client's home. This would ob-
viously mean that input from the client, in re-
lation to the completion of a questionnaire,
could be directly applied with minimum su-
pervision. Yates (1996) suggests that the cli-
ent is more likely to respond truthfully to a
computer questionnaire, and that computer
software questionnaires be perceived to hold
no threat, as long as adequate preparation
has been given on the use of the programme.
Thus, the client feels less inclined to give a
response that will 'please' or influence the
outcome.
Such systems, whilst expensive as an initial
outlay, recoup the value quickly, in time, and
man-hours saved, in collation and report
preparation. However, a word of warning,
Yates (1994) correctly suggests that the 'cli-
ent [service provider] may hold unrealis-
tic expectations and not appreciate the
changes in work practice required to ac-
commodate the new software.'
If investment in staff training is not made, then
the system will hold no value, however, with
sufficient training and support such systems
are invaluable to the service provider opera-
tional in the proactive field of service provi-
sion and justification. The alcohol depen-
dency system (ADS), as a package, has an
integrated monitoring and report process for
alcohol home detoxification. DISCLAIMER:
Whilst the author has evaluated the pack-
age, he is not an employee or agent of the
organisation.
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Who was asking the
question(s) and why
did they want the
Information?
After a preparatory phase of about three
years, a national project on medical prescrip-
tion of narcotics started in Switzerland near
the end of 1993. It was implemented by the
Federal Office of Public Health, based on
the Federal Government decree of 13 may
1992 on the “Advancement of the scientific
related research for drug prevention and im-
provement of living conditions of drug ad-
dicts” (Verordnung des Bundesrates 1992).
In the context of the official Swiss drug
policy, the prescription project was only one
in a number of initiatives to reduce drug re-
lated problems by preventive and therapeu-
tic interventions (Bundesratsbeschluss 1991).
Controlled medical prescription has been part
of the Swiss treatment system since the late
seventies, but restricted to oral narcotics,
mostly methadone. The new project included
prescription of intravenous heroin, morphine
and methadone. Especially the inclusion of
heroin raised great interest, as only England
The authors alone
are responsible for
the views expressed
in this case example.
had a tradition in prescribing pharmaceutical
heroin to heroin addicts, and only a few coun-
tries used it as a potent analgesic. The Swiss
experiment reopened the debate on the even-
tual usefulness of prescribing heroin to heroin
addicts in the framework of a therapeutic
setting.
A standing National Expert Committee on
drug problems commissioned a study to re-
view all international experience with mor-
phine and heroin prescription (Mino 1990).
The study invited further consideration of a
diversified prescription scheme, especially the
experiment with intravenous morphine for a
highly problematic group of heroin users in
Amsterdam (Derks 1990, Van Brussel
1995). The diversified prescription of nar-
cotics in Merseyside, England, also invited a
reconsideration of prescription practices, al-
though the original work of Dole and
Nyswander demonstrated specific advan-
tages of oral methadone in comparison to
injectable heroin. Further, heroin prescrip-
tion in British clinics was to a large extent
replaced in the eighties by prescribing oral
methadone (Gossop and Strang 1996). The
expert committee recommended further ex-
perimentation.
Case example of a
process evaluation
Medical Prescription of Narcotics
Background and Intermediate
Results of a Swiss National Project
by
A. Uchtenhagen
A. Dobler-Mikola
F. Gutzwiller
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The legal basis for an eventual experiment
with heroin for heroin addicts was clarified
by the Federal Department of Justice. The
narcotic law of 19951 in its article 8 pro-
vides that heroin can be used for scientific
purposes only. It was concluded that a sci-
entific experiment would be justified.
The main objective was to involve, in a thera-
peutic programme, those heroin addicts who
could not or not in a satisfactory way, be
contacted by existing treatment programmes.
This objective was in line with a policy de-
signed to make treatment available for the
largest possible proportion of heroin addicts.
The reduction of risk for the spread of HIV-
infections was the main motive in addition to
a reduction in other types of problems.
Information on scope, size and main condi-
tions of the project is summarised as follows:
Substances involved:
heroin, morphine, methadone
Application:
i.v., p.o., or smoked
Duration of project:
3 years (deadline Dec. 31, 1996)
Size of project:
original plan = 700 participants
(250 receiving heroin)
final plan = 1,000 participants
(800 receiving heroin)
Entry criteria:
• minimum age = 20
• heroin dependence = minimum of 2 years
• other treatment approaches failed
• social/health problems evident
• compliance with programme
• informed consent
Exclusion criteria:
• non-compliance with programme
• violence on the premises
Research agenda:
approved by National Government and by
Ethical Committee of Swiss Academy of
Medical Sciences
According to Narcotic Law, the project had
to be a combination of a scientific and a
therapeutic programme detailed as follows:
Therapeutic Programme:
• Comprehensive medical, psychiatric and
social assessment
• Comprehensive medical and psychoso-
cial care, including sheltered living (if
needed)
• On-site controlled injections (no take-
home of injectable substances)
Scientific Programme:
• Data collection from therapeutic
programme (medical examinations, labo-
ratory findings, daily dosages of pre-
scribed substances, other treatment data,
observations on behaviour e.a.)
• Data collection from independent inter-
viewers (self-report data on social and
medical history and status at regular in-
tervals)
• Data collection from third parties (medi-
cal records, criminal records)
What resources were
needed to collect
and interpret the
information?
A first proposal for such an experiment, in-
cluding the original research plan, was pre-
pared on behalf of the Federal Office of Pub-
lic Health, and with the approval of the
National Committee on Narcotics submitted
to National Government, to the National Eth-
ics Committee of the Swiss Academy of
Medical Sciences and to the Federal Data
Protection Officer (Bundesamt für
Gesundheitswesen 1993). The objectives
and the detailed working plan, being po-
litically, ethically and juridically approved
of, became officially acknowledged
in a Federal Government's decree
(Bundesratsbeschluss vom 13. Mai 1992).
A research group headed by the authors
was commissioned to conduct the evalua-
tion research. The researcher's work was
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to be supervised and accompanied by the
interdisciplinary National Expert Group of
the Federal Office of Public Health. This
office also initiated the manufacture and
control of the galenic forms (non-synthetic
pharmaceutical preparations) required for
the study. The International Narcotics
Control Board, a United Nations body
responsible for supervising the application
of international conventions on narcotics,
issued the permits for the importation of
the required amounts of heroin. Approval
procedures, operational security and lo-
gistics were discussed and organised in
collaboration with chief medical officers,
chief pharmacists and police authorities in
cantons where a sub-project was to be
realised.
How were the data
collected?
A comprehensive study protocol included
data to be collected from clinic staff, from
interviews organised by an independent re-
search group, as well as data from other
sources such as medical records and crimi-
nal records (Uchtenhagen et al 1994). All
data were rigorously protected: the iden-
tity of participants being known to the re-
spective clinics staff and to controlling au-
thorities (Federal Office of Public Health,
Cantonal Chief Medical Officer) only. The
research team worked with anonymised
data coded for evaluation purposes. Data
collection was organised in a standardised
form in order to allow an analysis of both
individual and pooled data. The range of
research questions is shown as follows:
Patient-related items:
• Changes in medical/psychiatric status
• Changes in addictive behaviour
• Changes in coping behaviour including
reduction of risk-taking
Substance-related items:
• Pharmacological/toxicological effects of
prescribed substances
• Bioavailability of substances
• Therapeutic applicability of various galenic
preparations
Service-related items:
• Feasibility of project
• Management of safety problems
• Cost-effectiveness of project
Global evaluation:
• Advantages/disadvantages in comparison
to substitution with oral methadone
• Recommendations for therapeutic prac-
tice and legislation
Patient-related and service-related items
were dealt with in a standardised format us-
ing questionnaires which to a large extent are
compatible with those used in the evaluation
of other methadone programmes and absti-
nence programmes. Substance-related data
were partly collected in a standardised form
for all participants, also, partly in specific
studies with a special protocol to be used in
subsamples.
As a comparison group, patients entering
regular methadone programs were docu-
mented and followed-up on the basis of the
same protocol. Not all sub-projects followed
the same design, varying from double-blind
and randomised allocation of substances to
individual indications (Fig. 1).
Double-blind studies are designed in order
to test effects of heroin against those of mor-
phine, excluding subjective expectations and
connotations. Rapid metabolisation of heroin
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to morphine in the human body makes this
study especially interesting. The randomised
studies respect the rules of trials according
to good clinical practice, whereas individual
indication mirrors therapeutic practice and
therefore allows for comparisons especially
with methadone programmes. One sub-
project was designed to serve especially
women (including sex-workers); its results
should be compared to those for other fe-
male participants.
The original research plan was subsequently
modified. The number of planned morphine
treatment slots was reduced following a num-
ber of unfavourable experiences with pre-
scribing intravenous morphine (frequent and
clearly adverse effects, poor acceptance).
For the same reasons, a similar reduction in
the number of slots for intravenous metha-
done was decided. On the other hand, the
Swiss Council of Minister’s Resolution of 30
January 1995 permitted an increase in the
number of heroine treatment slots to a maxi-
Figure 1: Original Research Plan
Objective Substances Design Controls
A specific effects heroin i.v. double-blind B
heroin-morphine morphine i.v.
B specific effects heroin i.v. randomised A
heroin-morphine morphine i.v.
C substance-specific effects heroin i.v. randomised D
morphine i.v.
methadone i.v.
D substance-specific effects heroin i.v. individual C
morphine i.v. indication oral methadone
methadone i.v.
E effects of specific heroin i.v. individual women from A-D
programme for women morphine i.v. indication
methadone i.v. oral methadone
mum 500. In addition to these changes in
sample size, the research record was supple-
mented by a comprehensive questionnaire on
criminal behaviour (Killias et al 1995).
In May 1995, the Swiss Council of Minis-
ters resolved to expand the programme with
additional questions and sub-projects. Thus,
the number of places for heroin prescription
increased further to 800, and the overall num-
ber of participants to 1000. Special research
records were used for the supplementary
questions, so as to avoid having to alter the
original research protocol. Additional ques-
tions regard the insertion of sub-projects into
existing methadone clinics, and the treatment
of patients with dual diagnosis.
What did they find out?
Intermediate results concern feasibility of the
project and the multi-centre study, the effects
and therapeutical applicability of substances,
the characteristics of participants, their re-
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tention and follow-up data. Two extensive
reports on intermediate results have been
published (Uchtenhagen et al 1996a,
Uchtenhagen et al 1996b).
Feasibility
The results on aspects of feasibility can be
summarised as follows:
• 7 out of 9 original sub-projects have been
realised in 1994 (with different
organisational structures and financial sup-
port)
• non-realisation of 2 sub-projects is due
to low acceptance for morphine injections
• 8 additional sub-projects have been
realised in 1995
• 4 referenda on sub-projects were held
with positive results
• no negative impact of prescription clinics
on neighbourhoods
• qualified staff recruited, low turnover
• no diversion of narcotic substances into
black market
• no severe cases of overdose
• 1210 persons were recruited as partici-
pants (drop-outs were allowed to be re-
placed until January 7, 1996)
Two of the originally authorised sub-projects
were not realised because the side effects of
intravenous morphine injections resulted in a
low acceptance for this modality and there-
fore two clinics which were foreseen to pre-
scribe morphine only could not recruit enough
participants. All the other sub-projects were
realised with the support from the respective
authorities in the cities of Basel, Bern,
Fribourg, Olten, Thun and Zürich. Accord-
ing to police information, no negative impact
on neighbourhoods was observed, in con-
trast to some negative expectations. While
the clinics were inserted into the existing thera-
peutic networks without difficulties; an even-
tual impact on other treatment approaches
will have to be analysed. Due to the on-site
controlled injections, no diversion of narcot-
ics substances into the black market took
place, an also no severe cases of overdose.
Additional sub-projects were realised in
Genf, Horgen, Luzern, Solothurn, St. Gallen,
Wetzikon, Winterthur and Zug. Referenda
were held in Basel and Zug.
The findings for the substances involved are
summarised as follows:
Morphine
• frequent histaminic-like reactions when
intravenously injected, especially in fe-
males
• correctly identified by participants in
double-blind trials due to side-effects
• low acceptance by participants
• long-acting oral morphine well accepted
when oral methadone not applicable
Methadone
• untoward local effects when intravenously
injected due to dosage
• low acceptance by participants
• oral methadone well accepted as basic
substitution medication in combination
with injectable heroin
Heroin
• negligible side effects when intravenously
injected
• stable dosages in most participants
• heroin cigarettes not satisfactory (low
bioavailability, side effects)
• slow-release tablets in experimentation
Conclusion:
Heroin more applicable intravenously in com-
parison to morphine and methadone; oral
application to be tested.
Intravenous morphine application was fol-
lowed more frequently and more severely by
histaminic-like reactions (local or
generalised). The side effects are similar to
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those already know in general medicine, but
intensified due to the higher dosages needed
in persons with fully developed opiate toler-
ance. The side effects are responsible for the
mostly correct identification of morphine in
double-blind studies, and also for a low ac-
ceptance by many participants (58% of those
receiving morphine left the project or
switched to heroin). MST continues, a long-
acting oral morphine preparation, on the other
hand, was well accepted and especially used
when oral methadone is not applicable.
Rather surprisingly, intravenous methadone
met a low acceptance as well. Side effects
at the site of injection may explain part of it,
probably also due to higher dosages (in com-
parison to British practice). However, we
cannot exclude a psychological negative ef-
fect in those participants who expected to
receive heroin but were given methadone in
a randomised fashion. On the other hand
again, oral methadone was well accepted by
participants in combination with injected
heroin, as it allows to reduce daily heroin in-
jections from three or four to one, therefore
reducing the need for multiple clinic visits
each day and facilitating employment and
other activities.
Heroin was also reported to have some side
effects similar to those observed in intrave-
nous morphine, but less severe. After an ini-
tial phase of several weeks, a stable dosage
could be reached by most participants, and
no unlimited increase of dosage was asked
for. The specially prepared tobacco-free
cigarettes, base on woodruff, standardised
with heroin solutions of 50mg and 100mg
proved to be not very satisfactory; up to 90%
of heroin was destroyed in the burning pro-
cess (tested in laboratory) and bioavailability
is accordingly low. Other forms of galenic
preparations such as slow-release tablets are
therefore in experimentation.
Description of participants
To what extent participants correspond to
entry criteria can be seen as follows:
Anamnestic data and findings at entry, co-
horts 1994 and 1995, participants receiving
heroin, n=786.
• average age 30.7 years
• average duration of heroin dependence
10.4 years
• unstable housing condition in 39%
• unemployed 82%
• illegal activities in 54%
• minimal or no contact outside of drug
scene in 39%
• court convictions in 84%, ever in prison
51%
• daily consumption of cannabis in 31%, of
cocaine in 34%, of alcohol in 19%, of
benzodiazepines in 25%
• former treatments: 91% methadone main-
tenance, 88% detoxification, 50% resi-
dential long-term treatment (mostly mul-
tiple treatments)
• somatic health impaired in 24%
• hepatitis in the past, 74%
• HIV seropositivity in 22%
• psychiatric hospitalizations in 48%
• suicidal attempts in 43%
• psychological health impaired in 42%
Conclusion:
Entry criteria are respected. Participants are
older, with a longer history of heroin depen-
dence, and more marginalized and impaired
in comparison to other treatment populations.
These data concern all participants which
entered the project in 1994 and 1995. This
cohort is, on the average, older than most
other treatment populations from residential
and methadone programmes, with a longer
duration of heroin dependence. The number
of former treatments, the amount of social
deficits including a high amount of delin-
quency, and also the amount of health im-
pairment demonstrate to what extent the en-
try criteria have been respected. The target
group for which the project was designed
could effectively be reached, although a mi-
nority only was out of any treatment contact
for the last six months before entry. This may
be seen as an effect of a comparatively high
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threshold due to the comprehensive thera-
peutic and scientific programme.
Follow-up results
Follow-up results on participants who en-
tered the project in 1994, are summarised
as follows:
Retention Rates and Drop-outs (Basis: 1994
cohort, participants receiving heroin, n=317.)
Retention rate:
• 82% during 6 months
• 67% during 15 months
Drop-outs during first 15 months:
• 54% of drop-outs changed to another
treatment modality (45% to methadone
maintenance, 9% to abstinence therapy)
• 35% discontinued treatment or were ex-
cluded for threat of violence or other se-
rious misbehaviour
• 11% were hospitalised, moved or died
(4 fatalities, no overdose)
• higher rate of daily cocaine use at entry
among drop-outs
• drop-outs who were excluded were more
marginalized at entry
Conclusion:
Higher retention rate in comparison to resi-
dential treatment, satisfactory in comparison
to methadone maintenance.
Retention rate during the first 15 months of
participation was higher than in most other
treatment programmes for heroin addicts in
the country. Half of those who dropped out
during the first six months went back to an-
other treatment modality, mostly to metha-
done maintenance. About 25% of drop-outs
had to be excluded for intolerable behaviour.
Four fatalities were recorded, mainly due to
chronic infectious disease.
Entry data of drop-outs indicate that partici-
pants with daily cocaine use at entry, those
engaged in prostitution and those with a his-
tory of aggressive acting-out behaviour were
over-represented among drop-outs. For the
following tabulation, participants only who
receive heroin, stayed for at least one year
and were able to perform the second fol-
low-up interview in time are included.
Basis:
206 of 366 participants entering trials during
1994 and receiving heroin (self-report data,
data from urine tests and police data; in
brackets data at entry):
• housing situation stable in 70% (64%)
• employment, no contact with drug scene
in 50% (16%)
• unemployed, frequent contact to drug
scene in 14% (50%)
• unemployed without contact to drug scene
in 36% (35%)
• illegal income in 14% (70%) according
to self-report, significant reduction in de-
linquency according to police reports
• reduction of daily illegal cocaine use from
31% to 7%, but minimal reduction of can-
nabis use from 34% to 32% and of ben-
zodiazepine use from 20% to 14% (self-
report and urine tests)
• prostitution, peddling etc. in 7% (46%)
• somatic health improved (significantly re-
duced injection-related syndromes and
troubles of the Autonomous Nervous
System)
• psychological health improved (signifi-
cantly reduced number of depressions and
paranoid states)
Conclusion:
Participants showed significant changes in
social and health status, including risk taking
behaviour.
Changes in social status were observed re-
garding housing situation and, more surpris-
ingly, employment rate. A reduction of illegal
activities and of contact with other drug us-
ers was based on self-report-data and on
police information (recorded delinquency
before and after entry into project during 6
month periods). Urine controls documented
a reduction of daily cocaine use, not of daily
cannabis and benzodiazepine use.
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Body-mass measures and injection-related
syndromes improved significantly (accord-
ing to number of abscesses and other der-
matological scores), as well as depressive-
suicidal syndromes and paranoid and anxiety
states. Other somatic problems and also ag-
gressive acting-out behaviour showed no sig-
nificant changes.
Final comments
By these first intermediate results, the fea-
sibility, safety and therapeutic applicability
of heroin prescription to heroin addicts
under adequate conditions are docu-
mented. Beneficial effects during the first
12 months of participation were also evi-
denced. This conclusion however cannot
be generalised. It concerns a specific and
most marginalized target population of ad-
dicts, and a prescription practice embed-
ded into a comprehensive assessment and
care programme.
Providing pharmaceutical heroin in this
project permits to attract addicts who fail in
multiple other treatment approaches and give
them a new opportunity to take courage and
to engage in a therapeutic and rehabilitation
programme, without being forced to abstain
from their preferred substance. It is not as-
sured yet, however, to what extent positive
changes in health and social status will con-
tinue over longer periods of time, and to what
extent a drug-free lifestyle can be reached
by participants in a later stage.
This experiment cannot be the basis for any
claim to support “free heroin”, but it could -
it the further evaluation results corroborate
the preliminary positive findings - add a
supplementary option for treating long-stand-
ing marginalized heroin addicts unable to profit
from other treatment approaches. This im-
plies that other treatment approaches have
to be available in good quality and sufficient
number, when such an additional option is
considered.
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Its your turn
What are the strengths and the weaknesses of the presented case example? List three posi-
tive aspect and three negative aspects:
Strengths of the case study
1
2
3
Weaknesses of the case study
1
2
3
